1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Aptevo Therapeutics Inc (APVO)
  7. Quote


Aptevo Therapeutics Stock Price

-0.91 (-11.32%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 659,579
Bid Price 7.05
Ask Price 7.48
News -
Day High 8.1352


52 Week Range


Day Low 6.92
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Aptevo Therapeutics Inc APVO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.91 -11.32% 7.13 00:00:05
Open Price Low Price High Price Close Price Prev Close
8.01 6.92 8.1352 7.03 8.04
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,303 659,579 $ 7.55 $ 4,979,682 - 6.38 - 47.98
Last Trade Time Type Quantity Stock Price Currency
19:56:40 16 $ 7.13 USD


Draw Mode:

Aptevo Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 34.92M 4.90M 2.88M $ 4.31M $ - -5.23 -1.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 45.40%

more financials information »

Aptevo Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical APVO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week12.8114.106.9211.093,698,155-5.68-44.34%
1 Month15.8022.07996.3815.7911,029,174-8.67-54.87%
3 Months17.1222.07996.3815.793,583,888-9.99-58.35%
6 Months26.0031.766.3815.941,691,239-18.87-72.58%
1 Year47.5347.986.3816.52885,320-40.40-85.0%
3 Years2.3460.000.19511.42742,9734.79204.7%
5 Years1.9260.000.1959.92544,8065.21271.35%

Aptevo Therapeutics Description

Aptevo Therapeutics Inc is a clinical-stage biotechnology company. It focuses on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. The company develops its drug candidates using its ADAPTIR platform. The products under its pipeline are APVO436, which targets CD123 and CD3 and redirects T-cell cytotoxicity to the tumor; ALG.APV-527, for the treatment of a broad spectrum of cancers over-expressing the 5T4 tumor antigen, including mesothelioma, non-small-cell-lung, head & neck, pancreatic, renal, ovarian, and bladder cancers; and APVO603.

Your Recent History
Aptevo The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.